CD8+ T cells play a central role in the control of viruses that persist within the host, such as HIV [1,2] and its simian counterpart [simian immunodeficiency virus (SIV)] . Despite considerable efforts to identify correlates of protective immunity against HIV, however, the precise attributes of CD8+ T cells that define antiviral efficacy are unclear. In part, this reflects the inherent difficulties associated with qualitative studies of CD8+ T-cell immunity, which include a requirement to control for inter-individual heterogeneity and the numerous parameters that govern target cell engagement. These latter variables include epitope specificity, T-cell receptor (TCR) affinity, TCR and CD8+ coreceptor density and valency, plasma membrane topography, differentiation status and regulatory molecule expression . In addition, CD8+ T-cell recognition is influenced by the state of the antigen-presenting cell, its ability to process and present the relevant epitope, the nature and expression levels of the restricting major histocompatibility complex class I (MHCI) molecule and the stability of the peptide–MHCI (pMHCI) complex. In HIV infection, the situation is further complicated by various immune evasion mechanisms deployed by the virus, including Nef-mediated MHCI down-regulation and mutational escape, both of which can directly impact antigen processing and presentation [5–14].
It has been shown that the ability of CD8+ T cells to suppress HIV replication in vitro associates with favorable disease outcome . This key observation demarcates a correlate of CD8+ T-cell efficacy in infected patients, yet the parameters that determine this functional property remain to be clarified. There is an emerging view that the functional avidity or antigen-sensitivity (AgS) of a CD8+ T-cell response greatly influences the control of HIV replication [16–18]. This qualitative attribute has been linked with TCR avidity, a compound measure of clonotype-dependent antigen engagement, although the supporting evidence is largely confined to studies of CD8+ T cells specific for the immunodominant Gag263–272 KK10 epitope presented by human leukocyte antigen (HLA)-B*2705 (HLA-B27 from hereon) [19–21], a molecule associated with superior control of HIV infection [22–24]. Moreover, there is no general consensus on the role of AgS as a determinant of CD8+ T-cell-mediated control of HIV replication. For instance, it has been suggested that high-avidity CD8+ T cells may not exert strong selection pressure on the virus because such cells were found to persist in late-stage disease despite the absence of mutations within the targeted viral epitopes . It has also been reported that protective polyfunctional CD8+ T cells display low, rather than high, avidities for HIV epitopes . Moreover, other studies suggest that HIV-specific CD8+ T-cell efficacy is related primarily to antigen specificity [26,27] and the kinetics of antigen expression . These divergent studies prompted us to investigate the impact of AgS and TCR avidity on HIV-suppressive capacity.
To minimize the confounding factors that arise as a function of heterogeneity, we have worked previously with CD8+ T-cell clones isolated from HIV-1-infected patients as an alternative to studying polyclonal responses directly ex vivo. This approach facilitates a simpler view of the different parameters that affect CD8+ T-cell efficacy. However, these studies were limited to a panel of CD8+ T-cell clones specific for the HLA-B27-restricted Gag263–272 KK10 epitope [19–21]. As a direct continuation of this study, we proceeded to examine the relationship between AgS and antiviral efficacy using CD8+ T cells specific for other immunodominant epitopes derived from different HIV-1 proteins and restricted by an alternative HLA class I molecule. To this end, we generated CD8+ T-cell clones specific for either the Nef73–82 QK10 epitope or the Gag20–29 RY10 epitope, both restricted by HLA-A*0301 (HLA-A3 from hereon), from HIV-1-infected patients. Equipped with a panel of CD8+ T-cell clones incorporating a range of sensitivities across three distinct specificities, we were able to study the effect of AgS on HIV-suppressive capacity independent of antigen source (Gag/Nef), epitope sequence (QK10/RY10/KK10), restricting HLA class I molecule (HLA-A3/HLA-B27) and viral strain (LAI/JR-CSF/DH12).
Materials and methods
Flow cytometry reagents
Tetrameric antigen complexes for QK10/HLA-A3, RY10/HLA-A3 and KK10/HLA-B27, all conjugated to phycoerythrin, were generated as described previously [29,30]. Directly conjugated monoclonal antibodies (mAbs) were purchased from commercial sources as follows: anti-CD4-allophycocyanin-cyanine7 (APC-Cy7), anti-CD8-APC-Cy7, anti-CD45RA-V450, anti-CCR7-PE-Cy7, anti-CD107a-PE-Cy5, anti-IFNγ-Alexa700, anti-IL-2 APC and anti-TNF-PE-Cy7 (BD Biosciences, San Diego, California, USA); anti-CD3-ECD and anti-p24 Gag-PE (Beckman Coulter, Miami, Florida, USA); (iii) anti-CD28-Alexa700 (Biolegend, San Diego, California, USA); (iv) anti-CD8-Alexa405 (Life Technologies, Eugene, Oregon, USA); and (v) anti-MIP-1β-fluorescein isothiocyanate (FITC; R&D Systems, Minneapolis, Minnesota, USA). The amine-reactive viability dye Aqua (Life Technologies) was used to eliminate dead cells from the analysis. Staining with all reagents was conducted according to standard procedures [31,32].
Peptides and viruses
Peptides corresponding to the HIV-1-derived epitopes QK10 (QVPLRPMTYK, Nef73–82), RY10 (RLRPGGKKKY, Gag20–29) and KK10 (KRWIILGLNK, Gag263–272) were synthesized commercially at above 95% purity (Biosynthesis Inc., Lewisville, Texas, USA). The HIV-1 viral isolates LAI, JR-CSF and DH12 (all clade B) were obtained from the National Institutes of Health AIDS reagent program and amplified on a mix of activated CD4+ T cells from three healthy donors.
CD8+ T-cell clones and cell lines
CD8+ T-cell clones specific for the HLA-A3/A11-restricted Nef epitope QK10 and the HLA-A3-restricted p17 Gag epitope RY10 were derived from peripheral blood mononuclear cell (PBMC) samples obtained from four HLA-A3+ patients during the chronic phase of HIV-1 infection. All donors were asymptomatic in the absence of antiretroviral therapy with CD4+ cell counts greater than 500 cells/μl and plasma viral loads ranging from 1000 to 250 000 copies of HIV-1 RNA/ml. Briefly, single tetramer+ CD8+ T cells were sorted using a FACSAria flow cytometer (BD Biosciences) in a biosafety containment level III laboratory and expanded in microtiter plates by periodic stimulation in the presence of mixed irradiated allogeneic PBMCs, phytohemagglutinin [phytohemagglutinin (PHA); 1 μg/ml] and recombinant human interleukin (rhIL)-2 (200 IU/ml). CD8+ T-cell clones specific for the HLA-B27-restricted p24 Gag epitope KK10 were generated and expanded as described previously . All CD8+ T-cell clones were cultured at 37°C/5% CO2 in R+ medium (Roswell Park Memorial Institute medium-1640 containing 2 mmol/l L-glutamine and antibiotics) supplemented with 5% human AB serum and 200 IU/ml rhIL-2. Primary HLA-A3+/HLA-B27+ CD4+ T cells were isolated by positive selection (MACS; Miltenyi Biotec, Paris, France) from healthy donor PBMCs cultured in R10 medium (R+ supplemented with 10% fetal calf serum) containing 200 IU/ml rhIL-2. HLA-A3+ Epstein–Barr virus (EBV)-transformed B-cell lines (HLA-A3+ LCLs) used to present exogenous antigen in interferon (IFN)γ enzyme-linked immunosorbent spot (ELISpot) assays were cultured in R10 medium. Unbiased molecular characterization of all expressed TCR gene rearrangements (i.e. clonotypic analysis) was performed as described previously [19,30,33,34].
Tetramer dilution assay
T-cell receptor avidity was measured using tetramer dilution assays. Briefly, CD8+ T-cell clones were incubated with cognate tetramer at a range of concentrations (10–0.0015 μg/ml in 1/3 dilutions) for 30 min at 4°C, then stained for CD8 expression before fixation. The percentage and fluorescence intensity of tetramer+ CD8+ T cells at each tetramer concentration was determined by flow cytometry.
Interferon gamma enzyme-linked immunosorbent spot assay
Each well of a 96-well polyvinylidene plate (Millipore, Paris, France) precoated with antihuman IFNγ capture mAb (Diaclone, Besançon, France) was subjected to 105 HLA-A3+ LCLs, 103 clonal CD8+ T cells and peptide at the desired concentration (ranging from 10−5 to 10−11 mol/l). Plates were then incubated overnight at 37°C/5% CO2 and developed according to the manufacturer's instructions (Mabtech, Nacka Strand, Sweden). Spots were counted using an automated ELISpot reader (Carl Zeiss MicroImaging Inc., Le Pecq, France). A PHA control (final concentration 1 μg/ml) was included for each CD8+ T-cell clone. All assays were performed in duplicate and normalized.
CD8+ T-cell clones and HLA-A3+ LCLs pulsed with the indicated concentrations of cognate peptide were incubated at an effector : target (E : T) ratio of 1 : 10 for 1 h with anti-CD107a and a further 5 h in the presence of monensin (2.5 μg/ml; Sigma-Aldrich, St. Louis, Missouri, USA) and brefeldin A (5 μg/ml; Sigma-Aldrich) at 37°C/5% CO2. Negative controls were processed likewise in the absence of peptide. Staining for intracellular markers was performed as described previously . Data were acquired using a Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJo software version 9.4.4 (TreeStar Inc., Ashland, Oregon, USA). Doughnut plots were constructed using Excel software and polyfunctionality indices were calculated as described previously .
Viral suppression assay
Primary HLA-A3+/HLA-B27+ CD4+ T cells were stimulated for 48 h with PHA (1 μg/ml) and cultured for 7 days in the presence of 100 IU/ml rhIL-2 to facilitate productive HIV infection. The cells were then plated out at 105 cells/well in a 96-well plate and infected with virus by spinoculation . Infected CD4+ T cells were cocultured with clonal CD8+ T cells at different E : T ratios as indicated. Three days later, the cells were harvested and stained with Aqua. Surface staining for CD8 and CD4 and intracellular staining for p24 were then conducted to enable flow cytometric evaluation of HIV-infected target cell elimination.
Characterization of CD8+ T-cell clones specific for HLA-A3-restricted HIV epitopes
Previously, we generated and characterized a set of CD8+ T-cell clones specific for the HLA-B27-restricted KK10 epitope (KRWIILGLNK, p24 Gag263–272) to investigate the determinants of HIV-suppressive capacity in vitro [19–21]. To extend these studies across different epitopes and HLA class I restriction elements, we generated CD8+ T-cell clones specific for two highly conserved HIV-1-derived epitopes restricted by HLA-A3: QK10 (QVPLRPMTYK, Nef73–82) and RY10 (RLRPGGKKKY, p24 Gag20–29). Nine clones with equivalent surface expression levels of CD3+ and CD8+ were established in total (A3-QK10, n = 5; A3-RY10, n = 4) from the peripheral blood of HIV-1-infected patients with the appropriate HLA class I genotype (n = 4).
The functional avidity or AgS of these A3-QK10 and A3-RY10 clones was assessed using dose titrations of exogenous cognate peptide in the presence of an HLA-A3+ target cell line and quantified as the EC50 value, defined as the concentration required to elicit a half-maximal response, in IFNγ ELISpot assays. A range of sensitivities was observed for both sets of clones (Fig. 1a). We also used tetramer dilution assays, which focus specifically on the TCR–pMHCI interaction and eliminate the confounding influences of other molecular interactions that can occur in contiguous membrane domains, to measure TCR avidity (Fig. 1b). This parameter takes into account the intrinsic binding strength (affinity) of the TCR and the role of the CD8+ coreceptor, as well as the density, topography and coordinate relationship of these antigen-binding receptors within the constraints of cell surface mobility. The percentage of tetramer+ cells was quantified by flow cytometry as a function of tetramer concentration and used to calculate TCR avidity (i.e. EC50 value) for both sets of clones (Fig. 1c).
A significant correlation was observed between measures of AgS and TCR avidity for the different clones (Fig. 1d). This indicates that TCR avidity is a major determinant of AgS, consistent with our previous study [19–21]. The EC50 values for both the A3-QK10 and A3-RY10 clones, despite their different specificities, spanned a narrow range (tetramer dilution: 0.029–0.002 μg/ml; IFNγ ELISpot: 1.55 × 10–7 to 1.49 × 10–8 mol/l). This is not entirely surprising as virus-specific CD8+ T cells generally display relatively high levels of AgS and TCR avidity, reflecting relatively high monomeric TCR–pMHCI affinities . Nevertheless, this initial characterization led to the identification of CD8+ T-cell clones with distinct TCR avidities, thereby enabling us to examine a putative link between this parameter and HIV-suppressive capacity.
CD8+ T-cell clones with high T-cell receptor avidities suppress HIV replication efficiently
Next, we assessed the ability of CD8+ T-cell clones restricted by HLA-A3 or HLA-B27 to suppress HIV replication in vitro as a function of TCR avidity. For this purpose, we selected pairs of A3-QK10 and A3-RY10 clones to include high and low TCR avidity representatives. Two previously characterized B27-KK10 clones with markedly different TCR avidities were also included for comparison [19,20]. Clonotypic analysis confirmed that the selected A3-QK10 and A3-RY10 clones expressed unique TCRs (Fig. 2a). Consistent with our earlier findings in the B27-KK10 system [19–21], the functional profile of CD8+ T-cell clones restricted by HLA-A3 was intimately associated with TCR avidity (Fig. 2b). All clones exhibited a homogeneous CD28− CCR7− CD45RA− effector memory phenotype (Fig. 2c).
Dual HLA-A3+/HLA-B27+ primary CD4+ T cells were used as infected targets to enable meaningful comparative analyses of HIV-suppressive capacity across restriction elements. These cells were infected with the X4-tropic LAI laboratory strain of HIV-1, which was titrated in the absence of CD8+ T cells to achieve an infectivity of 10–20%, determined by intracellular p24 staining [9,37]. Target cells infected with HIV-1 LAI were combined with each CD8+ T-cell clone at E : T ratios ranging from 0.01 : 1 to 1 : 1. Infected targets alone were incorporated as a reference for infectivity in the absence of CD8+ T cells. No alloreactivity was detected in these assays. The percentage of p24 staining obtained at each E : T ratio was then used as a quantitative measure of HIV-suppressive activity, with the most potent CD8+ T-cell clones achieving the lowest p24 levels at the lowest E : T ratios (Fig. 3a).
For each specificity, the higher TCR avidity CD8+ T-cell clone consistently suppressed HIV replication more efficiently than its lower TCR avidity partner (Fig. 3b). Across specificities, however, the relationship between TCR avidity and HIV-suppressive activity was less robust (Fig. 3c). For instance, although the A3-RY10 clones displayed higher TCR avidities and higher levels of AgS than the corresponding A3-QK10 clones, they were consistently less efficient at suppressing HIV replication. Thus, the relationship between TCR avidity and HIV-suppressive capacity only held true within a given specificity. These observations suggest that the restricting HLA class I molecule and/or the cognate epitope delimit the antiviral efficacy of CD8+ T cells.
CD8+ T-cell clones exhibit differential strain-dependent HIV-suppressive capacity
In further experiments, we examined CD8+ T-cell-mediated suppression of the R5-tropic JR-CSF and X4R5-tropic DH12 laboratory stains of HIV-1. Again, HLA-A3+/HLA-B27+ primary CD4+ T-cell targets were spinoculated with titrated doses of each viral strain to achieve a final infectivity of approximately 20% (Fig. 4a). Individual CD8+ T-cell clones displayed marked differences in their ability to suppress HIV replication across different strains (Fig. 4b). For instance, the B27-KK10 and A3-QK10 clones suppressed LAI effectively, JR-CSF modestly and DH12 poorly. In contrast, the A3-RY10 clones suppressed all three viruses suboptimally.
Epitope sequence differences provide a potential explanation for these discrepancies in antiviral efficacy (Fig. 4c). In particular, the reduced suppressive activity of the A3-QK10 and B27-KK10 clones against DH12 likely reflects the presence of point mutations in the targeted epitopes (e.g. L268M for KK10 and V74I for QK10). Instead, recognition of the RY10 epitope on DH12-infected CD4+ T cells was presumably less affected due to the lack of antigenic sequence variation. The L268M mutation in KK10 can impair TCR recognition at the cell surface and represents a clonotype-specific escape variant for the high-avidity B27-KK10 clone used in this study . The V74I mutation in QK10 could act similarly, affecting TCR–pMHC interaction, thus reducing CD8+ T-cell clone efficacy to inhibit DH12 replication. Indeed, the A3-QK10 clone 4G3 displayed impaired recognition of the V74I peptide, with a 1 log lower functional avidity for the variant peptide compared to the wild-type peptide (data not shown), consistent with the viral suppression data (Fig. 4b). Moreover, the epitope-flanking mutations present in JR-CSF and DH12 might impede antigen processing , thereby contributing to the reduced antiviral efficacy of A3-QK10 clones against these isolates.
In this study, we used CD8+ T-cell clones with distinct epitope specificities and HLA class I restriction elements to investigate the relationship between AgS, TCR avidity and HIV-suppressive capacity. Consistent with our previous observations in the B27-KK10 system , we found that TCR avidity and AgS were directly correlated across panels of HLA-A3-restricted CD8+ T-cell clones specific for the HIV epitopes QK10 and RY10, thereby reinforcing the central role of the TCR as a determinant of functional potency. Furthermore, within each specificity, CD8+ T-cell clones with higher TCR avidities consistently suppressed HIV replication more efficiently than their lower TCR avidity counterparts. However, this association did not hold between specificities. Moreover, the hierarchy of antiviral CD8+ T-cell efficacy varied across different HIV-1 strains, even when the cognate epitope sequence was conserved. Consequently, it is difficult to draw a general parallel between antiviral efficacy and either AgS or TCR avidity, which explains the lack of consensus in the current literature.
The use of peptide antigens or single viral strains to determine antiviral CD8+ T-cell efficacy is intrinsically limited. In a recent study, Dong and colleagues examined the activity of CD8+ T-cell clones specific for the HLA-B8-restricted Nef90–97 FL8 epitope (FLKEKGGL) in response to target cells infected with different HIV-1 strains or recombinant vaccinia viruses expressing different isolate-derived Nef proteins . Despite conservation of the FL8 sequence across all viruses tested, only 23% were recognized. This suboptimal response rate was attributed to epitope-flanking region polymorphisms in the majority of viral isolates, which impaired cognate antigen generation. Our data further highlight the potential bias associated with noninclusive in-vitro systems.
Additional factors beyond sequence variation can affect antigen presentation and confound comparisons between antiviral efficacy and either AgS or TCR avidity. For example, the Nef protein is expressed early in the HIV replication cycle and processed/presented before synthesis of the structural proteins, such as Gag . In addition, although the majority of HLA class I-restricted epitopes are processed by the proteasome or immunoproteasome, the Nef-derived QK10 epitope is unusual in that it is generated by an aminopeptidase enzyme called tripeptidyl peptidase II (TPPII) . Taking both factors into account, the QK10 epitope may therefore exhibit different and likely more rapid processing/presentation kinetics compared to the RY10 and KK10 epitopes. Together with competition for binding to the HLA-A3 molecule, these kinetic differences could explain why the A3-QK10 clones outperformed the A3-RY10 clones in HIV-suppression assays despite lower overall TCR avidities.
The nature of the restricting HLA class I molecule is also noteworthy. In the present study, we performed all HIV-suppression assays using a single target cell line expressing both HLA-A3 and HLA-B27 to standardize our approach across restriction elements. Nonetheless, we cannot account for the relative densities of these molecules on the target cell surface. Techniques such as high-affinity TCR microscopy [42,43] or micro-Raman spectroscopy  would be required to compare HLA-A3 and HLA-B27 expression levels directly. Furthermore, these HLA class I molecules may be differentially susceptible to Nef-mediated down-regulation. Indeed, it was recently demonstrated that HLA-A molecules are down-regulated by Nef to a greater extent than HLA-B molecules . Irrespective of TCR avidity, such differences could explain the greater potency of HLA-B27-restricted clones compared to HLA-A3-restricted clones. In line with these considerations, epitope expression kinetics and Nef-mediated HLA class I down-regulation have been reported previously to influence the HIV-suppressive capacity of CD8+ T cells [46,47].
Finally, it is important to consider the possibility that interclonal differences in functional potential, for example, due to epigenetic regulation , could affect comparisons of antiviral efficacy irrespective of other parameters. In addition, the differential sensitivity of viral isolates to nonlytic suppression mediated by soluble factors, such as CC-chemokines and IL-16 [49,50], might explain some of the observed variability in our system.
To conclude, our data show that the relationship between HIV-suppressive capacity and either AgS or TCR avidity is blurred by the multiple factors that can affect CD8+ T-cell recognition of cognate pMHCI molecules on the target cell surface. Thus, the correlation between TCR avidity, AgS and antiviral activity holds within, but not necessarily between, antigen specificities. Collectively, these observations emphasize the importance of the TCR as a key determinant of CD8+ T-cell efficacy and help resolve purported discrepancies in the field.
We thank Catherine Blanc for sorting viable tetramer+ cells at the Pitié-Salpêtrière Flow Cytometry Platform, and Martin Larsen for help with polyfunctionality index calculations.
Funding: This work was supported by Sidaction, the French Agence Nationale de la Recherche sur le SIDA (ANRS) and the ANR (Project ANR-09-JCJC-0114-01). DAP is a Wellcome Trust Senior Investigator.
Conflicts of interest
The authors declare that they have no competing financial interests.
1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
. J Virol
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
. J Virol
3. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
4. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease
. Nat Med
5. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design
. Nat Rev Immunol
6. Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, et al. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response
. J Exp Med
7. Cardinaud S, Consiglieri G, Bouziat R, Urrutia A, Graff-Dubois S, Fourati S, et al. CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope
. PLoS Pathog
8. Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, Le Gall S, et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection
. J Virol
9. Zimbwa P, Milicic A, Frater J, Scriba TJ, Willis A, Goulder PJ, et al. Precise identification of a human immunodeficiency virus type 1 antigen processing mutant
. J Virol
10. Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
. Nat Immunol
11. Milicic A, Price DA, Zimbwa P, Booth BL, Brown HL, Easterbrook PJ, et al. CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef
. J Immunol
12. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C, et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection
. J Exp Med
13. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
14. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
. Nat Med
15. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype
. Proc Natl Acad Sci U S A
16. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover
. J Exp Med
17. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, Hartman KL, et al. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control
. J Virol
18. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control
. PLoS One
19. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, Moris A, et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity
20. Iglesias MC, Almeida JR, Fastenackels S, van Bockel DJ, Hashimoto M, Venturi V, et al. Escape from highly effective public CD8+ T-cell clonotypes by HIV
21. Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, et al. A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells
22. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child
. J Virol
23. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
. Nat Med
24. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
. Nat Med
25. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, Tapia G, et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype
. Proc Natl Acad Sci U S A
26. Yang OO, Sarkis PT, Trocha A, Kalams SA, Johnson RP, Walker BD. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL
. J Immunol
27. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker BM, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes
. J Virol
28. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, et al. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells
. J Virol
29. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes
30. Price DA, Brenchley JM, Ruff LE, Betts MR, Hill BJ, Roederer M, et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses
. J Exp Med
31. Whelan JA, Dunbar PR, Price DA, Purbhoo MA, Lechner F, Ogg GS, et al. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent
. J Immunol
32. Papagno L, Almeida JR, Nemes E, Autran B, Appay V. Cell permeabilization for the assessment of T lymphocyte polyfunctional capacity
. J Immunol Methods
33. Douek DC, Betts MR, Brenchley JM, Hill BJ, Ambrozak DR, Ngai KL, et al. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape
. J Immunol
34. Price DA, West SM, Betts MR, Ruff LE, Brenchley JM, Ambrozak DR, et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection
35. Larsen M, Sauce D, Arnaud L, Fastenackels S, Appay V, Gorochov G. Evaluating cellular polyfunctionality with a novel polyfunctionality index
. PLoS One
36. Bridgeman JS, Sewell AK, Miles JJ, Price DA, Cole DK. Structural and biophysical determinants of alphabeta T-cell antigen recognition
37. Loffredo JT, Burwitz BJ, Rakasz EG, Spencer SP, Stephany JJ, Vela JP, et al. The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape
. J Virol
38. Couillin I, Connan F, Culmann-Penciolelli B, Gomard E, Guillet JG, Choppin J. HLA-dependent variations in human immunodeficiency virus Nef protein alter peptide/HLA binding
. Eur J Immunol
39. Ranasinghe SR, Kramer HB, Wright C, Kessler BM, di Gleria K, Zhang Y, et al. The antiviral efficacy of HIV-specific CD8(+) T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate
. PLoS Pathog
40. Kim S, Ikeuchi K, Byrn R, Groopman J, Baltimore D. Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1
. Proc Natl Acad Sci U S A
41. Seifert U, Maranon C, Shmueli A, Desoutter JF, Wesoloski L, Janek K, et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope
. Nat Immunol
42. Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, et al. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors
. J Immunol
43. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor
. Nat Med
44. Das G, La Rocca R, Lakshmikanth T, Gentile F, Tallerico R, Zambetti LP, et al. Monitoring human leukocyte antigen class I molecules by micro-Raman spectroscopy at single-cell level
. J Biomed Opt
45. Rajapaksa US, Li D, Peng YC, McMichael AJ, Dong T, Xu XN. HLA-B may be more protective against HIV-1 than HLA-A because it resists negative regulatory factor (Nef) mediated down-regulation
. Proc Natl Acad Sci U S A
46. Ali A, Lubong R, Ng H, Brooks DG, Zack JA, Yang OO. Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes
. J Virol
47. Chen DY, Balamurugan A, Ng HL, Cumberland WG, Yang OO. Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes
48. Olson MR, Russ BE, Doherty PC, Turner SJ. The role of epigenetics in the acquisition and maintenance of effector function in virus-specific CD8 T cells
. IUBMB Life
49. Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16
50. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells